Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans
Abstract Psilocybin is an active alkaloid found in magic mushrooms (Psilocybe cubensis). It is classified as a Class I Psychoactive Substance due to its psychoactive properties. Recent research has suggested that psilocybin holds potential for treating major depressive disorder. The objective of thi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-98202-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849713517164232704 |
|---|---|
| author | Nilubon Thaoboonruang Ornrat Lohitnavy Kimheang Ya Manupat Lohitnavy |
| author_facet | Nilubon Thaoboonruang Ornrat Lohitnavy Kimheang Ya Manupat Lohitnavy |
| author_sort | Nilubon Thaoboonruang |
| collection | DOAJ |
| description | Abstract Psilocybin is an active alkaloid found in magic mushrooms (Psilocybe cubensis). It is classified as a Class I Psychoactive Substance due to its psychoactive properties. Recent research has suggested that psilocybin holds potential for treating major depressive disorder. The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for psilocybin and its active metabolite, psilocin, in mice, rats, and humans. This model aims to explore the disposition of psilocin within the body, including its distribution to the target organ, the brain. Psilocybin is assumed to undergo complete conversion to psilocin before the latter enters systemic circulation. The PBPK model effectively characterizes the concentration-time profiles under various dosing scenarios and routes of administration in mice, rats, and humans. The human model has the potential for guiding therapeutic strategies and enhancing clinical trial designs for the therapeutic use of psilocybin. |
| format | Article |
| id | doaj-art-22d9724246e54697bf35e135a684d813 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-22d9724246e54697bf35e135a684d8132025-08-20T03:13:57ZengNature PortfolioScientific Reports2045-23222025-04-0115111210.1038/s41598-025-98202-wDevelopment of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humansNilubon Thaoboonruang0Ornrat Lohitnavy1Kimheang Ya2Manupat Lohitnavy3Center of Excellence for Environmental Health and Toxicology, Faculty of Pharmaceutical Sciences, Naresuan UniversityCenter of Excellence for Environmental Health and Toxicology, Faculty of Pharmaceutical Sciences, Naresuan UniversityCenter of Excellence for Environmental Health and Toxicology, Faculty of Pharmaceutical Sciences, Naresuan UniversityCenter of Excellence for Environmental Health and Toxicology, Faculty of Pharmaceutical Sciences, Naresuan UniversityAbstract Psilocybin is an active alkaloid found in magic mushrooms (Psilocybe cubensis). It is classified as a Class I Psychoactive Substance due to its psychoactive properties. Recent research has suggested that psilocybin holds potential for treating major depressive disorder. The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for psilocybin and its active metabolite, psilocin, in mice, rats, and humans. This model aims to explore the disposition of psilocin within the body, including its distribution to the target organ, the brain. Psilocybin is assumed to undergo complete conversion to psilocin before the latter enters systemic circulation. The PBPK model effectively characterizes the concentration-time profiles under various dosing scenarios and routes of administration in mice, rats, and humans. The human model has the potential for guiding therapeutic strategies and enhancing clinical trial designs for the therapeutic use of psilocybin.https://doi.org/10.1038/s41598-025-98202-wMagic mushroomsPsilocybe cubensisPsilocybinPsilocinPBPK |
| spellingShingle | Nilubon Thaoboonruang Ornrat Lohitnavy Kimheang Ya Manupat Lohitnavy Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans Scientific Reports Magic mushrooms Psilocybe cubensis Psilocybin Psilocin PBPK |
| title | Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans |
| title_full | Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans |
| title_fullStr | Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans |
| title_full_unstemmed | Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans |
| title_short | Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans |
| title_sort | development of a pbpk model of psilocybin psilocin from psilocybe cubensis magic mushroom in mice rats and humans |
| topic | Magic mushrooms Psilocybe cubensis Psilocybin Psilocin PBPK |
| url | https://doi.org/10.1038/s41598-025-98202-w |
| work_keys_str_mv | AT nilubonthaoboonruang developmentofapbpkmodelofpsilocybinpsilocinfrompsilocybecubensismagicmushroominmiceratsandhumans AT ornratlohitnavy developmentofapbpkmodelofpsilocybinpsilocinfrompsilocybecubensismagicmushroominmiceratsandhumans AT kimheangya developmentofapbpkmodelofpsilocybinpsilocinfrompsilocybecubensismagicmushroominmiceratsandhumans AT manupatlohitnavy developmentofapbpkmodelofpsilocybinpsilocinfrompsilocybecubensismagicmushroominmiceratsandhumans |